Safety and Immunogenicity of Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic Combined With Infusion of Treg Depleted T Cells for Adult WT1 Acute Myeloid Leukemia

PHASE1/PHASE2UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2014

Conditions

Acute Myelogenous LeukemiaMyeloid Leukemia in RemissionEffects of Immunotherapy

Interventions

BIOLOGICAL

Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)

i.m. administration

Trial Locations (1)

RECRUITING

Institut Jules Bordet, tumor center of the Universite Libre de Bruxelles, Brussels